(01)Overview
Retatrutide (LY3437943) is a single-molecule agonist of the GIP, GLP-1, and glucagon receptors, studied for its combined effects on metabolic signalling, energy expenditure, and hepatic lipid handling.
The 20mg format is intended for laboratories running longer or higher-throughput study designs, reducing vial count and handling steps per protocol.
Retatrutide remains an investigational compound and is not approved for any therapeutic use. Each vial is lyophilized, sealed under sterile conditions, and traceable to a batch Certificate of Analysis.
Research areas
- Metabolic & weight-regulation research
What retatrutide is
Retatrutide (LY3437943) is a synthetic peptide developed as a single molecule that activates three receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). A fatty-acid side chain promotes binding to serum albumin, which is what gives the molecule its extended half-life in published pharmacokinetic studies.
Why researchers study it
Most incretin research compounds act on one or two of these receptors. A tri-agonist lets a lab compare GIPR, GLP-1R and GCGR signalling with a single reference compound, which is why retatrutide appears in metabolic, energy-expenditure and hepatic lipid research. Typical in-vitro work includes receptor-binding and cAMP-accumulation assays in cell lines expressing each receptor.
Regulatory status
Retatrutide is an investigational compound. Clinical-stage findings have been published (for example Jastreboff et al., NEJM 2023), but it is not approved for any therapeutic use. Darkside Labs supplies it strictly as a research material for laboratory work.






